{"ticker": {"uuid": "f1224815-cddd-4bfb-8dc3-fe2858461148", "symbol": "LGND", "name": "Ligand Pharmaceuticals Incorporated", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Ligand Pharmaceuticals Incorporated Stock 12\u2011Month Price Target Raised to $278.5, Implies 1% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxPdXZNU094Q29ISWRrWjBHTUdDalNLeGVIUmM0ZDg1QzRkWVFuU09zS2dSRXZ2RlFLZXFPbWlxVS1sdVVpTTBxbUp1M0tKUDdwWVVNLWY5MUFKS0UzekktMXh3dWdOUGdrS3BPZHdINnVxWnBCM0tPRkZUUzFiZEE5bndsS0NqcDZmeVZ0SG45bDROMkktdjlMQ1k5SHdUWk56dEZoNkhMR2ctM0Ridkh6UkpoZWpCd0gwRURSMnJjUnN3M3dxbDJUOWM4SVBadnJvT0hkUkd1X2VJS3otSGZKSEpFOE1qa0FLSnZYZ1lWYw?oc=5", "source_name": "TradingView", "published_at": "2026-06-22T16:20:06+00:00", "published_display": "22 Jun 2026 16:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Plans $550M Convertible Notes Offe", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQOExLV0ExdFpfZHFKMWdHODVzd0ZZTmVEOHE5MjEwQVdSVDhFZVFTRTlqN3QxQVZGTVJZeTBtMUVpRmVOLVJlazFTT1hjNHZveHIyTVBKWmdlNEd2U1BVQkljbVhlMUxUWllvdlhHUjV4XzZvazhMb2ZTazIzUXZlWHBJenB0bWNUN013UENPdXJCMEJRTUpLWW53SzU5b05ZNnEyZS1odw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T13:25:44+00:00", "published_display": "22 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Plans $550 Million Convertible Notes Offering Due 2031", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-plans-550-million-121615810.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:16:15+00:00", "published_display": "22 Jun 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Ligand Pharmaceuticals stock sliding today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxObmUyNTdjT1lDUDZuVy1yazFCaFE5WDlsTEFhWExmTXJuYjc3cnoybWR6VGF5VDFjMnl5WlBaekg0ZEY0X0V3Mlp0SVVXTFBTSjlSY0hsSlkyWjRMNEo3UGF3TUQ4eEJhQ0wyaVFjZVlWZnp4SmNZemVWZXFyanhxdmxqdUpTcUVtZkRVejBqRWtDVFc4VEhTNGtWZ0lzNVR2TW91bU9EcXA2SU5YVjBmQw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T12:01:09+00:00", "published_display": "22 Jun 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) sets $550M convert deal and $75M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNZWwtVEwzR0o1RTlaVTZkM3N2TEo2NjdKVThFRVRrcnlDY0gzamFRWG5CRjI5Z0dGVU1LQWU4U2lxMWI5dk9mdFRzQ2kwWXJST1hfOXh4ZDhobVpvbkhoT0kybW1hQ1Uwb3dRelBGeVFLaWFPVVRQTC1rdlVnbHkwLS1POGFZR0ZYWDJSM1J5b1dfS2VEazloLUNkU2xXcVc3cXhLZkgweDFvLVR5Z1JKbEdteDVPdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T11:11:41+00:00", "published_display": "22 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-announces-proposed-offering-550-110000217.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand seeks $550M in notes, plus share repurchases to limit dilution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcVFtb3o0V2pneFFaV3RwR0I0NU1zSjRoU3ljSXR1eHNUYWdLMXZLSU9vMlNzMVhYeHRWajBvSlNhNHBUYS13RDZoMEFjMHAyTmE1bFN4b2RyM2Q0a19pZFI5RjVTTWJRTnhUTEtfTnlSem1FNm1IWHltX19oOExNTEp3TTRtOXRoa2xQSWtaVDJ4YjZSSVhXVUhvakx4TUZ1YjFLQzl0MEstZHktbFdWSXYtUDVrZjI4YTlv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Is Up 7.6% After Institutions Snap Up the Float and Earnings Jump \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T22:58:23+00:00", "published_display": "19 Jun 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Insider Sold Shares Worth $544,830, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-insider-sold-shares-124147571.html", "source_name": "MT Newswires", "published_at": "2026-06-18T12:41:47+00:00", "published_display": "18 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) director exercises options and sells 2,145 common shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVkVha2VMVVUzMGhZcTU5a1k1QUN6N3lzSWFJaG04aHU5bVNQV2MzcUVjRm9iUmxWR0h2NDRBbUh4V3VKRWFkYjVESTZCUXhQTkh2QVYxOTRnVy1GVmNVWS1KMWd2Q2lBaGZiZXI5eTF5eHNkbnIyYldBTGQ4U0ZnYWVvWWM2RmgweDdDaHZtcF9CMVZBc2hvMjZZUUUwX0szd3pZX05sQzBPdV9fMU5Wa19JaFdJd185U2hYWg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:37:48+00:00", "published_display": "18 Jun 2026 12:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Stock - Insider option exercise and institutional selling", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPSnZUZE81ME1LRV9XcGo3Ukw1LVZkbjhMMlI2bzllQUdfNHVOM2h4bXBfVlc5V2x4eENhdHhoM3p1ak1SODdoNERkSndpY1FmUzVESzRBOUIxZWZmSmIybzhucEpsS1JYc1B5Ny1rQ19pX2h3N1dWWklsZ3NIempjR3lPb0h0QktnUUlfVXlaV0pPNVZBYzJDTkRwN25Rc1NqSWt6UzllNDJnTDlYMmVocE12UklwNk45X2xyYW44TzhWOEhyRG8xMg?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-17T14:49:06+00:00", "published_display": "17 Jun 2026 14:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND (NASDAQ) insider files Form 144 showing 1,000-share sale and June option-related sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPaUFaR3lld3ZFWWlXNTByYlZGQkl1aFBldjVwMWlUQlF2dHdMeXFnc3ZjNkY2TVFndGdqZVlOZ2thckpFRUFscDlRQk92TmhMVGl2MXcwQVdvSWtPSktPZVVwZmJKYXdOdTU0SXMtZ2dLb2E2Q0JMN2FaMldpaGliTHZXYm8wd2ZHdmpKR2NfWWtzc2dYQkROeVFLeXFxSnpxSmwwZDV3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:30:36+00:00", "published_display": "16 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Stock Could Be 33% Below Fair Value After Its Recent Run", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T09:42:51+00:00", "published_display": "16 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Insider Sold Shares Worth $1,651,320, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-insider-sold-shares-074600083.html", "source_name": "MT Newswires", "published_at": "2026-06-16T07:46:00+00:00", "published_display": "16 Jun 2026 07:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (LGND) director exercises options, sells 6,461 common shares around $255\u2013$256", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZUtiR0JFUTFwWEk3WkYtcVlYRG1sVHdPRWxYRTFWWHUtMzZxVE5RVWxubW54VkszZWNrRmRtWVdfVWJNWVhoc3hRY0tjMVhRVy1aU1FtRG84cko4cWxFbk83eWJDSFlReThSMXIxWUtjR3FaRW5wODJSSXptYTBDeGh4RzliYzF6empsZEQwV0lmeHl6YkFRd2wwak5rUnNFWWIzSHdGQXVpaDBna2Y5akdPQVpKTV9lTEZMWg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T01:21:50+00:00", "published_display": "16 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Director Unloads 2,501 Shares \u2014 Should You Be Concerned?", "summary": "", "url": "https://finance.yahoo.com/m/c6b2a3fd-a114-3978-a8a4-7fd1a94d06c3/ligand-pharmaceuticals.html", "source_name": "Motley Fool", "published_at": "2026-06-14T11:20:01+00:00", "published_display": "14 Jun 2026 11:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Stock 9-Day Winning Spree: Stock Climbs 11%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQYVdMSmlac1g3Tm1GTjZ1aDRMeHhuUVExdUlsRk1BdXpONGdfVl9EWHVoZ2kxUHdQNjgyZk5kMmliU0c2ZlNFMlU0WmJhOThpdkgxcEJJSHZkb0dlVk8zUkhFd2ZvakxiZk9fSDIwNTQ5T1p4cF84WGNRRklzVU44MnQyVVJuaXJfQW5Ra3FnYlllVk1mTk1uVjZZQ0ktRU9LMUtMTG15QVNfeFkxM21vSUh3OUlFZUdjeEQ0amMxdlZpbi12NHdlN0FLYklfVkFH?oc=5", "source_name": "Trefis", "published_at": "2026-06-13T05:08:20+00:00", "published_display": "13 Jun 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Stock Rockets 11% With 9-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNeGdVNHNGMFNzMXpuLWJMZFh0Zy1zTnNaSHFaNXJCQVpseEMtZW93UUhFUHRVUVhVRVJIcFAzYzNHeDVjY1ZISnl4WFlWODVQVndIQlhmWGdfazczU2pUeEs0V3JHeEtQV1V6MUpCMC1sRV9ydU1YQXhaTklvUDAzQXI2VWI1T3V0MllrWGhfUE1tMHBSWS1QcnQzWWRPZjk3N0daUkFrZFYwbzRNVnE0dnFuUkxDSW4xVlVSQXJSa3ZRcW9s?oc=5", "source_name": "Trefis", "published_at": "2026-06-13T05:01:05+00:00", "published_display": "13 Jun 2026 05:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND (NASDAQ) Form 144 shows 4,000-share option exercise and restricted stock notices", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOWUkzNW9LR2J3QU9hUm4wR2tBUDNjSHdYUm94UG5EOVljQ0xoc1h3VzVDNmstWDJnSzI4bFpWczktdHNjTG5CSXpQZTJwaFU3QlUwQXRGQVBNcUk1eXhoWk8wbHdlaUU5czV0SE5BZWt0Sm1YZE1Ld1dpbWRCZU1zMTRaTVRCcmluVG9tTXdKc1M0TU1PUVRNWllUMzV1ZzNJRzkwcjd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:31+00:00", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director sells 4,591 Ligand (LGND) shares in multiple open-market trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTS1KcDNTZGt5cm1QQUl2cUxrNEdRYnUtT3MxaGVmVGh3Z012eEowWWN4WjNoZE5HcF9YVW51Sk13RW9KNFMzeGIxWm93X2QxQkU4MTV6WGpkLXMxdnd2TXg3SmNoWkJlVHBrUGRQMlZCUElaaHdYeUNkRHhvaWpwcGxNdlFfQTh1c2U4T3hJc2wtUDJzd0hnNndpazhVTW9pYW9ZaHdSbXYxRE1HR00zWDhYR2licFFyTENQTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked funds trim Ligand (LGND) stake with 5,000-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQU2FWMTJJUVYwNmVnOGtUQzRmaWlzUzVNOG1tTENQdVp6a2N6Z0pwYmtDNDBIbjRORS1wVU81b0t4by0wbWlnSmxTQWFfbHRlN2xxYWdvQUlMLTltTk1kWmsxa0laLV92ZnpmdGpUOThHVVRkQzNvemFMNTRKbWd3NlZFVEpTRGdHSDA1VjFrbk5xUXMwMVpiMkVhTXJmTkFSV083N09FWEtBNmE0UXlMemFCdWJDLUhBbEdFVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo", "summary": "JALAA Equities LP reported the sale of 500 common shares of Ligand Pharmaceuticals (LGND) on June 10, 2026, for $124,980.42. The SEC filing also indicated 4,500 common shares associated with Wells Fargo Clearing Services, originally purchased on April 28, 2005. This Rule 144 noti", "url": "https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-9a3fe4b9d2c9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:37", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Reassess Ligand Pharmaceuticals (LGND) After A 115% One-Year Rally?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan", "summary": "Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its stockholders approved all proposals at the 2026 annual meeting. These approvals included the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting fi", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-2152b67b1c2f.html", "source_name": "Stock Titan", "published_at": "2026-06-10T18:09:10", "published_display": "10 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Announces 2026 Investor Day in New York City", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-announces-2026-investor-day-110000764.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:00:00+00:00", "published_display": "10 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] LIGAND PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNMTdWSWZ1UGlTUXF5bjg0Q3l6ajFfSUVzU0ltSW9jSjJLem9abGF4UFdwMEpXdkFlRXA4ZUpwQWR5WTR6SEc0UTBKMTJaZDlSb3BKRXNITEFKUldObFREVW1TcXRGd016aTFxN0ozS0hTTnpSN0VrVkhsUUN3WjlGMkhyWlB6UFUzTVlqcF81eXN1S21sV3BOV3B0S3FwOFpwM2o2S0Rn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants", "summary": "Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards comprising 836 restricted stock units (RSUs) and 2,938 non-qualified stock options with a strike price of $237.00 per share. These awards, granted on June 5, 2026, fully vest on the earlier of the company", "url": "https://www.stocktitan.net/sec-filings/LGND/form-4-ligand-pharmaceuticals-inc-insider-trading-activity-241ba3f79ea3.html", "source_name": "Stock Titan", "published_at": "2026-06-10T07:40:28", "published_display": "10 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition", "summary": "Martine Zimmermann, a director at LIGAND PHARMACEUTICALS INC (LGND), reported receiving 836 restricted stock units (RSUs) and non-qualified stock options for 2,938 shares on June 5, 2026, as part of her routine equity compensation. The RSUs and options will fully vest on the earl", "url": "https://www.stocktitan.net/sec-filings/LGND/form-4-ligand-pharmaceuticals-inc-insider-trading-activity-72e3b6efebb9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T05:40:19", "published_display": "10 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million", "summary": "Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares of Common Stock for approximately $1.14 million on June 1, 2026, by exercising stock options. This transaction represents a liquidity event tied to vesting long-term incentive awards, not an exit ", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-insider-sold-124838566.html", "source_name": "Market source", "published_at": "2026-06-07T08:48:00", "published_display": "07 Jun 2026 08:48", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Insider Sold Shares Worth $1,135,316, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-insider-sold-shares-073503605.html", "source_name": "MT Newswires", "published_at": "2026-06-03T07:35:03+00:00", "published_display": "03 Jun 2026 07:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)", "summary": "Levi & Korsinsky, LLP has launched an investigation into Robinhood, Interactive Brokers, and other trading platforms following trading bans and forced liquidations affecting investors in Ligand Pharmaceuticals (NASDAQ: LGND). These actions, which occurred on January 28, 2021, and", "url": "https://www.newsfilecorp.com/release/73129/Levi-Korsinsky-LLP-National-Class-Action-Law-Firm-Announces-Class-Action-Investigation-Against-Robinhood-and-Other-Brokers-on-Behalf-of-Investors-in-Ligand-Pharmaceuticals-Incorporated-NASDAQ-LGND?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-03T03:39:33", "published_display": "03 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 16, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) CLO sells 5,000 shares, exercises options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQcmttcDlhcG9NRzRxMlZKYXA0YklONlR0V09tU2E1MVBOSTgzRmdJSGVTclRFRjJrSXl6RE9RTmd3ak9qWVc4OXNUbk45WWhkbmxqRm5xeTJDQjh1SlN0TVlwaW9qUWhJc1VZTi05bnlWRVZ1Ylo1eTNESlRveURjaFI5TFozeDcxMDBqSUc2d1ZYWFhFWUNvb1ZfN3A1QjQ2Q2V1cUE0aExpQmR1OXBEbFl3QmVITFREeXVhSA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ligand Pharmaceuticals (LGND) Investment Story Is Evolving Without Fresh Analyst Targets", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-investment-story-131714147.html", "source_name": "Simply Wall St.", "published_at": "2026-06-01T13:17:14+00:00", "published_display": "01 Jun 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis", "summary": "Ligand Pharmaceuticals (Nasdaq:LGND) is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. The company recently agreed to acquire XOMA Royalty Corporation for $739 million, significantly expanding its royalty portfolio and leading to an upli", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-05-26T11:39:36", "published_display": "26 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND: XOMA Buy Adds 100+ Assets", "summary": "Ligand Pharmaceuticals (NASDAQ: LGND) announced the acquisition of XOMA Royalty Corporation (NASDAQ: XOMA) for $739 million, adding over 100 assets to its portfolio. The all-cash transaction, expected to close in Q3 2026, is projected to be immediately accretive to Ligand's earni", "url": "https://scr.zacks.com/news/news-details/2026/LGND-XOMA-Buy-Adds-100-Assets-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-05-20T21:40:32", "published_display": "20 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company", "summary": "Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings, facilitating a Nevada holding company reorganization. This change will result in Ligand's Merger Sub merging with HoldCo, which will then become a wholly owned subsidiary o", "url": "https://www.tradingview.com/news/tradingview:19c64383e002f:0-ligand-pharmaceuticals-amends-xoma-royalty-merger-agreement-to-add-holding-company/", "source_name": "TradingView", "published_at": "2026-05-19T09:10:58", "published_display": "19 May 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company", "summary": "Ligand Pharmaceuticals (LGND) has amended its merger agreement with XOMA Royalty Corporation to include XOMA Royalty Holdings Corporation as a party, formalizing a Nevada holding company reorganization. This amendment clarifies the legal structure of the previously announced acqu", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-410835941783.html", "source_name": "Stock Titan", "published_at": "2026-05-19T09:10:57", "published_display": "19 May 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND", "summary": "Stephens Investment Management Group LLC decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 9.6% in the fourth quarter, though it remains its 16th largest holding. Despite positive analyst sentiment and a \"Moderate Buy\" consensus rating, the company reported mixed qua", "url": "https://www.marketbeat.com/instant-alerts/filing-stephens-investment-management-group-llc-cuts-stock-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-05-17/", "source_name": "MarketBeat", "published_at": "2026-05-17T14:10:25", "published_display": "17 May 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed", "summary": "Ligand Pharmaceuticals reported strong Q1 2026 results with royalty revenue increasing 56% year-over-year to $43.0 million, primarily driven by products like Filspari, Ohtuvayre, and Capvaxive. Despite a GAAP net loss of $13.3 million due to non-cash items, adjusted net income ro", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-d09558e82e6f.html", "source_name": "Stock Titan", "published_at": "2026-05-14T07:09:22", "published_display": "14 May 2026 07:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND", "summary": "UBS Group AG significantly increased its stake in Ligand Pharmaceuticals, purchasing 31,081 additional shares in the fourth quarter, bringing its total holding to 143,067 shares valued at approximately $27.05 million. This comes amidst mixed analyst sentiment, with several firms ", "url": "https://www.marketbeat.com/instant-alerts/filing-ubs-group-ag-purchases-31081-shares-of-ligand-pharmaceuticals-incorporated-lgnd-2026-05-10/", "source_name": "MarketBeat", "published_at": "2026-05-12T07:39:51", "published_display": "12 May 2026 07:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination", "summary": "Ligand Pharmaceuticals (LGND) recently reported an earnings miss, higher royalty revenues, a planned acquisition of XOMA, and a disputed termination of the Viking TR-Beta licensing program. Despite these developments, the stock has shown positive momentum over the past few months", "url": "https://finance.yahoo.com/markets/stocks/articles/look-ligand-pharmaceuticals-lgnd-valuation-111534266.html", "source_name": "Market source", "published_at": "2026-05-10T09:40:30", "published_display": "10 May 2026 09:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Returns To Trailing Profitability Challenging Cautious Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty to Be Acquired by Ligand in $39-Per-Share Cash Deal Plus CVRs", "summary": "XOMA Royalty has agreed to be acquired by Ligand Pharmaceuticals for $39.00 per share in cash, plus contingent value rights (CVRs) from RemainCo LLC. The deal awaits HSR clearance and stockholder approval, with key XOMA stakeholders, including BVF Partners, already committed to s", "url": "https://www.tradingview.com/news/tradingview:3c2d28cdec3d4:0-xoma-royalty-to-be-acquired-by-ligand-in-39-per-share-cash-deal-plus-cvrs/", "source_name": "TradingView", "published_at": "2026-05-07T04:09:26", "published_display": "07 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Higher 2026 Guidance and XOMA Deal Just Shift Ligand Pharmaceuticals' (LGND) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to Participate in May Investor Conferences", "summary": "Ligand Pharmaceuticals announced its senior management team will participate in several investor conferences throughout May 2026, including the H.C. Wainwright Royalty Company Conference, Bank of America Healthcare Conference, CJS Securities Spring 1x1 Conference, H.C. Wainwright", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ligand-participate-may-investor-conferences-200100710.html", "source_name": "Market source", "published_at": "2026-05-05T17:39:52", "published_display": "05 May 2026 17:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the sales of XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. The firm is examining potential violations of federal securities laws and breaches of fiduciary duties to shareholders,", "url": "https://www.sahmcapital.com/news/content/are-xoma-rmax-kalv-obtaining-fair-deals-for-their-shareholders-2026-05-04", "source_name": "Sahm", "published_at": "2026-05-05T02:09:45", "published_display": "05 May 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake", "summary": "Vanguard Capital Management has filed a Schedule 13G on Ligand Pharmaceuticals Inc. (LGND), reporting a beneficial ownership of 997,637 shares, which represents a 5% stake in the company's common stock as of March 31, 2026. The filing indicates Vanguard possesses sole dispositive", "url": "https://www.stocktitan.net/sec-filings/LGND/schedule-13g-ligand-pharmaceuticals-inc-passive-investment-disclosure-12b076e4bd29.html", "source_name": "Stock Titan", "published_at": "2026-05-01T12:39:09", "published_display": "01 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)", "summary": "Vanguard Portfolio Management has reported a 5.56% beneficial ownership stake in Ligand Pharmaceuticals Inc. (NASDAQ: LGND), holding 1,109,154 shares. The Schedule 13G filing indicates sole voting power over 8,887 shares and sole dispositive power over all 1,109,154 shares. This ", "url": "https://www.stocktitan.net/sec-filings/LGND/schedule-13g-ligand-pharmaceuticals-inc-passive-investment-disclosure-de8992a27e47.html", "source_name": "Stock Titan", "published_at": "2026-05-01T12:39:09", "published_display": "01 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event", "summary": "Ligand Pharmaceuticals Inc. (LGND) filed an 8-K report announcing the termination of the TR-Beta Program under its Master License Agreement with Viking Therapeutics, Inc., effective May 4, 2026. Ligand asserts that Viking materially breached its obligation to use commercially rea", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-40920220ed7f.html", "source_name": "Stock Titan", "published_at": "2026-04-30T21:09:42", "published_display": "30 Apr 2026 21:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPQXI4bTdBamwzMVNNREMtbTB1OVRfZGNOOFRCYUQ0MUg0aFdMNkg5cG1EY000cDNvTTVrUG5TZGE1SHc1WGlUMHQzNHNxbnVhTEpQQ2NienIzbG8xSVZDLWR6OWRNcU43ejQwVDE0eUdRMWlJZjRqeE1adWtOaTJndU5WN1pDcGpqU09VaEZ4VnhzRXZHengxYVhpTmY2cDQ3SHp0Zw?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND", "summary": "B. Metzler seel. Sohn & Co. AG has invested $1.30 million in Ligand Pharmaceuticals (NASDAQ:LGND) by purchasing 6,879 shares in Q4, bringing institutional ownership to approximately 91.28%. Despite this, company insiders, including the CFO and a director, have recently sold share", "url": "https://www.marketbeat.com/instant-alerts/filing-b-metzler-seel-sohn-co-ag-invests-130-million-in-ligand-pharmaceuticals-incorporated-lgnd-2026-04-27/", "source_name": "MarketBeat", "published_at": "2026-04-28T00:39:09", "published_display": "28 Apr 2026 00:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs", "summary": "Ligand Pharmaceuticals has entered into a definitive merger agreement to acquire XOMA Royalty for $39.00 per share in cash, along with contingent value rights (CVRs) tied to a CVR Trust. The deal is contingent on XOMA Royalty stockholder approval, HSR clearance, and a holding com", "url": "https://www.tradingview.com/news/tradingview:80f3a7f8fea2d:0-ligand-pharmaceuticals-to-acquire-xoma-royalty-for-39-per-share-plus-cvrs/", "source_name": "TradingView", "published_at": "2026-04-28T00:39:09", "published_display": "28 Apr 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS\u2011accretive deal", "summary": "Ligand Pharmaceuticals announced its agreement to acquire XOMA Royalty Corporation for $739 million in cash, equating to $39.00 per share plus a contingent value right tied to Janssen litigation proceeds. This acquisition will significantly expand Ligand's biopharma royalty portf", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-67f9ae07b50f.html", "source_name": "Stock Titan", "published_at": "2026-04-28T00:09:42", "published_display": "28 Apr 2026 00:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND", "summary": "Impax Asset Management Group plc reduced its stake in Ligand Pharmaceuticals Incorporated by 17.5%, selling 35,000 shares and now holding 165,208 shares valued at approximately $31.24 million. Despite this sale, Ligand Pharmaceuticals reported strong quarterly results with EPS of", "url": "https://www.marketbeat.com/instant-alerts/filing-impax-asset-management-group-plc-sells-35000-shares-of-ligand-pharmaceuticals-incorporated-lgnd-2026-04-25/", "source_name": "MarketBeat", "published_at": "2026-04-25T13:10:14", "published_display": "25 Apr 2026 13:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND", "summary": "Assetmark Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 4,933.3%, now owning 6,191 shares valued at approximately $1.17 million. Analysts maintain a \"Moderate Buy\" consensus with a price target of $247.29, following strong quarterly earnings wh", "url": "https://www.marketbeat.com/instant-alerts/filing-assetmark-inc-raises-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-04-22/", "source_name": "MarketBeat", "published_at": "2026-04-22T10:08:52", "published_display": "22 Apr 2026 10:08", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) posts strong 2025 growth and seeks approval for expanded equity plan", "summary": "Ligand Pharmaceuticals (LGND) is seeking stockholder approval for an expanded equity plan at its June 5, 2026, annual meeting, following a strong financial performance in 2025. The company reported a 48% increase in royalty revenue and a 42% rise in adjusted EPS, driven by its ro", "url": "https://www.stocktitan.net/sec-filings/LGND/def-14a-ligand-pharmaceuticals-inc-definitive-proxy-statement-ce0cc5d0efc1.html", "source_name": "Stock Titan", "published_at": "2026-04-21T20:40:15", "published_display": "21 Apr 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Ligand Pharmaceuticals Incorporated Stock 12\u2011Month Price Target Raised to $278.5, Implies 1% Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxPdXZNU094Q29ISWRrWjBHTUdDalNLeGVIUmM0ZDg1QzRkWVFuU09zS2dSRXZ2RlFLZXFPbWlxVS1sdVVpTTBxbUp1M0tKUDdwWVVNLWY5MUFKS0UzekktMXh3dWdOUGdrS3BPZHdINnVxWnBCM0tPRkZUUzFiZEE5bndsS0NqcDZmeVZ0SG45bDROMkktdjlMQ1k5SHdUWk56dEZoNkhMR2ctM0Ridkh6UkpoZWpCd0gwRURSMnJjUnN3M3dxbDJUOWM4SVBadnJvT0hkUkd1X2VJS3otSGZKSEpFOE1qa0FLSnZYZ1lWYw?oc=5", "source_name": "TradingView", "published_at": "2026-06-22T16:20:06+00:00", "published_display": "22 Jun 2026 16:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Plans $550M Convertible Notes Offe", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQOExLV0ExdFpfZHFKMWdHODVzd0ZZTmVEOHE5MjEwQVdSVDhFZVFTRTlqN3QxQVZGTVJZeTBtMUVpRmVOLVJlazFTT1hjNHZveHIyTVBKWmdlNEd2U1BVQkljbVhlMUxUWllvdlhHUjV4XzZvazhMb2ZTazIzUXZlWHBJenB0bWNUN013UENPdXJCMEJRTUpLWW53SzU5b05ZNnEyZS1odw?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-22T13:25:44+00:00", "published_display": "22 Jun 2026 13:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Plans $550 Million Convertible Notes Offering Due 2031", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-plans-550-million-121615810.html", "source_name": "MT Newswires", "published_at": "2026-06-22T12:16:15+00:00", "published_display": "22 Jun 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Ligand Pharmaceuticals stock sliding today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxObmUyNTdjT1lDUDZuVy1yazFCaFE5WDlsTEFhWExmTXJuYjc3cnoybWR6VGF5VDFjMnl5WlBaekg0ZEY0X0V3Mlp0SVVXTFBTSjlSY0hsSlkyWjRMNEo3UGF3TUQ4eEJhQ0wyaVFjZVlWZnp4SmNZemVWZXFyanhxdmxqdUpTcUVtZkRVejBqRWtDVFc4VEhTNGtWZ0lzNVR2TW91bU9EcXA2SU5YVjBmQw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T12:01:09+00:00", "published_display": "22 Jun 2026 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) sets $550M convert deal and $75M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNZWwtVEwzR0o1RTlaVTZkM3N2TEo2NjdKVThFRVRrcnlDY0gzamFRWG5CRjI5Z0dGVU1LQWU4U2lxMWI5dk9mdFRzQ2kwWXJST1hfOXh4ZDhobVpvbkhoT0kybW1hQ1Uwb3dRelBGeVFLaWFPVVRQTC1rdlVnbHkwLS1POGFZR0ZYWDJSM1J5b1dfS2VEazloLUNkU2xXcVc3cXhLZkgweDFvLVR5Z1JKbEdteDVPdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T11:11:41+00:00", "published_display": "22 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-announces-proposed-offering-550-110000217.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand seeks $550M in notes, plus share repurchases to limit dilution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQcVFtb3o0V2pneFFaV3RwR0I0NU1zSjRoU3ljSXR1eHNUYWdLMXZLSU9vMlNzMVhYeHRWajBvSlNhNHBUYS13RDZoMEFjMHAyTmE1bFN4b2RyM2Q0a19pZFI5RjVTTWJRTnhUTEtfTnlSem1FNm1IWHltX19oOExNTEp3TTRtOXRoa2xQSWtaVDJ4YjZSSVhXVUhvakx4TUZ1YjFLQzl0MEstZHktbFdWSXYtUDVrZjI4YTlv?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Is Up 7.6% After Institutions Snap Up the Float and Earnings Jump \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-19T22:58:23+00:00", "published_display": "19 Jun 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Insider Sold Shares Worth $544,830, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-insider-sold-shares-124147571.html", "source_name": "MT Newswires", "published_at": "2026-06-18T12:41:47+00:00", "published_display": "18 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) director exercises options and sells 2,145 common shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNVkVha2VMVVUzMGhZcTU5a1k1QUN6N3lzSWFJaG04aHU5bVNQV2MzcUVjRm9iUmxWR0h2NDRBbUh4V3VKRWFkYjVESTZCUXhQTkh2QVYxOTRnVy1GVmNVWS1KMWd2Q2lBaGZiZXI5eTF5eHNkbnIyYldBTGQ4U0ZnYWVvWWM2RmgweDdDaHZtcF9CMVZBc2hvMjZZUUUwX0szd3pZX05sQzBPdV9fMU5Wa19JaFdJd185U2hYWg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T12:37:48+00:00", "published_display": "18 Jun 2026 12:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Stock - Insider option exercise and institutional selling", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxPSnZUZE81ME1LRV9XcGo3Ukw1LVZkbjhMMlI2bzllQUdfNHVOM2h4bXBfVlc5V2x4eENhdHhoM3p1ak1SODdoNERkSndpY1FmUzVESzRBOUIxZWZmSmIybzhucEpsS1JYc1B5Ny1rQ19pX2h3N1dWWklsZ3NIempjR3lPb0h0QktnUUlfVXlaV0pPNVZBYzJDTkRwN25Rc1NqSWt6UzllNDJnTDlYMmVocE12UklwNk45X2xyYW44TzhWOEhyRG8xMg?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-17T14:49:06+00:00", "published_display": "17 Jun 2026 14:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND (NASDAQ) insider files Form 144 showing 1,000-share sale and June option-related sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPaUFaR3lld3ZFWWlXNTByYlZGQkl1aFBldjVwMWlUQlF2dHdMeXFnc3ZjNkY2TVFndGdqZVlOZ2thckpFRUFscDlRQk92TmhMVGl2MXcwQVdvSWtPSktPZVVwZmJKYXdOdTU0SXMtZ2dLb2E2Q0JMN2FaMldpaGliTHZXYm8wd2ZHdmpKR2NfWWtzc2dYQkROeVFLeXFxSnpxSmwwZDV3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T20:30:36+00:00", "published_display": "16 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Stock Could Be 33% Below Fair Value After Its Recent Run", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T09:42:51+00:00", "published_display": "16 Jun 2026 09:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Insider Sold Shares Worth $1,651,320, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-insider-sold-shares-074600083.html", "source_name": "MT Newswires", "published_at": "2026-06-16T07:46:00+00:00", "published_display": "16 Jun 2026 07:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (LGND) director exercises options, sells 6,461 common shares around $255\u2013$256", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZUtiR0JFUTFwWEk3WkYtcVlYRG1sVHdPRWxYRTFWWHUtMzZxVE5RVWxubW54VkszZWNrRmRtWVdfVWJNWVhoc3hRY0tjMVhRVy1aU1FtRG84cko4cWxFbk83eWJDSFlReThSMXIxWUtjR3FaRW5wODJSSXptYTBDeGh4RzliYzF6empsZEQwV0lmeHl6YkFRd2wwak5rUnNFWWIzSHdGQXVpaDBna2Y5akdPQVpKTV9lTEZMWg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-16T01:21:50+00:00", "published_display": "16 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Director Unloads 2,501 Shares \u2014 Should You Be Concerned?", "summary": "", "url": "https://finance.yahoo.com/m/c6b2a3fd-a114-3978-a8a4-7fd1a94d06c3/ligand-pharmaceuticals.html", "source_name": "Motley Fool", "published_at": "2026-06-14T11:20:01+00:00", "published_display": "14 Jun 2026 11:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Stock 9-Day Winning Spree: Stock Climbs 11%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQYVdMSmlac1g3Tm1GTjZ1aDRMeHhuUVExdUlsRk1BdXpONGdfVl9EWHVoZ2kxUHdQNjgyZk5kMmliU0c2ZlNFMlU0WmJhOThpdkgxcEJJSHZkb0dlVk8zUkhFd2ZvakxiZk9fSDIwNTQ5T1p4cF84WGNRRklzVU44MnQyVVJuaXJfQW5Ra3FnYlllVk1mTk1uVjZZQ0ktRU9LMUtMTG15QVNfeFkxM21vSUh3OUlFZUdjeEQ0amMxdlZpbi12NHdlN0FLYklfVkFH?oc=5", "source_name": "Trefis", "published_at": "2026-06-13T05:08:20+00:00", "published_display": "13 Jun 2026 05:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Stock Rockets 11% With 9-Day Winning Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNeGdVNHNGMFNzMXpuLWJMZFh0Zy1zTnNaSHFaNXJCQVpseEMtZW93UUhFUHRVUVhVRVJIcFAzYzNHeDVjY1ZISnl4WFlWODVQVndIQlhmWGdfazczU2pUeEs0V3JHeEtQV1V6MUpCMC1sRV9ydU1YQXhaTklvUDAzQXI2VWI1T3V0MllrWGhfUE1tMHBSWS1QcnQzWWRPZjk3N0daUkFrZFYwbzRNVnE0dnFuUkxDSW4xVlVSQXJSa3ZRcW9s?oc=5", "source_name": "Trefis", "published_at": "2026-06-13T05:01:05+00:00", "published_display": "13 Jun 2026 05:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND (NASDAQ) Form 144 shows 4,000-share option exercise and restricted stock notices", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOWUkzNW9LR2J3QU9hUm4wR2tBUDNjSHdYUm94UG5EOVljQ0xoc1h3VzVDNmstWDJnSzI4bFpWczktdHNjTG5CSXpQZTJwaFU3QlUwQXRGQVBNcUk1eXhoWk8wbHdlaUU5czV0SE5BZWt0Sm1YZE1Ld1dpbWRCZU1zMTRaTVRCcmluVG9tTXdKc1M0TU1PUVRNWllUMzV1ZzNJRzkwcjd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:31+00:00", "published_display": "12 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director sells 4,591 Ligand (LGND) shares in multiple open-market trades", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTS1KcDNTZGt5cm1QQUl2cUxrNEdRYnUtT3MxaGVmVGh3Z012eEowWWN4WjNoZE5HcF9YVW51Sk13RW9KNFMzeGIxWm93X2QxQkU4MTV6WGpkLXMxdnd2TXg3SmNoWkJlVHBrUGRQMlZCUElaaHdYeUNkRHhvaWpwcGxNdlFfQTh1c2U4T3hJc2wtUDJzd0hnNndpazhVTW9pYW9ZaHdSbXYxRE1HR00zWDhYR2licFFyTENQTA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director-linked funds trim Ligand (LGND) stake with 5,000-share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQU2FWMTJJUVYwNmVnOGtUQzRmaWlzUzVNOG1tTENQdVp6a2N6Z0pwYmtDNDBIbjRORS1wVU81b0t4by0wbWlnSmxTQWFfbHRlN2xxYWdvQUlMLTltTk1kWmsxa0laLV92ZnpmdGpUOThHVVRkQzNvemFMNTRKbWd3NlZFVEpTRGdHSDA1VjFrbk5xUXMwMVpiMkVhTXJmTkFSV083N09FWEtBNmE0UXlMemFCdWJDLUhBbEdFVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo", "summary": "JALAA Equities LP reported the sale of 500 common shares of Ligand Pharmaceuticals (LGND) on June 10, 2026, for $124,980.42. The SEC filing also indicated 4,500 common shares associated with Wells Fargo Clearing Services, originally purchased on April 28, 2005. This Rule 144 noti", "url": "https://www.stocktitan.net/sec-filings/LGND/144-ligand-pharmaceuticals-inc-sec-filing-9a3fe4b9d2c9.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:39:37", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Reassess Ligand Pharmaceuticals (LGND) After A 115% One-Year Rally?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan", "summary": "Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its stockholders approved all proposals at the 2026 annual meeting. These approvals included the election of eight directors, the ratification of Ernst & Young LLP as the independent registered public accounting fi", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-2152b67b1c2f.html", "source_name": "Stock Titan", "published_at": "2026-06-10T18:09:10", "published_display": "10 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Announces 2026 Investor Day in New York City", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-announces-2026-investor-day-110000764.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:00:00+00:00", "published_display": "10 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] LIGAND PHARMACEUTICALS INC SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNMTdWSWZ1UGlTUXF5bjg0Q3l6ajFfSUVzU0ltSW9jSjJLem9abGF4UFdwMEpXdkFlRXA4ZUpwQWR5WTR6SEc0UTBKMTJaZDlSb3BKRXNITEFKUldObFREVW1TcXRGd016aTFxN0ozS0hTTnpSN0VrVkhsUUN3WjlGMkhyWlB6UFUzTVlqcF81eXN1S21sV3BOV3B0S3FwOFpwM2o2S0Rn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants", "summary": "Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards comprising 836 restricted stock units (RSUs) and 2,938 non-qualified stock options with a strike price of $237.00 per share. These awards, granted on June 5, 2026, fully vest on the earlier of the company", "url": "https://www.stocktitan.net/sec-filings/LGND/form-4-ligand-pharmaceuticals-inc-insider-trading-activity-241ba3f79ea3.html", "source_name": "Stock Titan", "published_at": "2026-06-10T07:40:28", "published_display": "10 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition", "summary": "Martine Zimmermann, a director at LIGAND PHARMACEUTICALS INC (LGND), reported receiving 836 restricted stock units (RSUs) and non-qualified stock options for 2,938 shares on June 5, 2026, as part of her routine equity compensation. The RSUs and options will fully vest on the earl", "url": "https://www.stocktitan.net/sec-filings/LGND/form-4-ligand-pharmaceuticals-inc-insider-trading-activity-72e3b6efebb9.html", "source_name": "Stock Titan", "published_at": "2026-06-10T05:40:19", "published_display": "10 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million", "summary": "Andrew Reardon, CLO & Secretary at Ligand Pharmaceuticals (LGND), sold 5,000 shares of Common Stock for approximately $1.14 million on June 1, 2026, by exercising stock options. This transaction represents a liquidity event tied to vesting long-term incentive awards, not an exit ", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-insider-sold-124838566.html", "source_name": "Market source", "published_at": "2026-06-07T08:48:00", "published_display": "07 Jun 2026 08:48", "sentiment": "positive", "sentiment_pct": 62, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Insider Sold Shares Worth $1,135,316, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-insider-sold-shares-073503605.html", "source_name": "MT Newswires", "published_at": "2026-06-03T07:35:03+00:00", "published_display": "03 Jun 2026 07:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)", "summary": "Levi & Korsinsky, LLP has launched an investigation into Robinhood, Interactive Brokers, and other trading platforms following trading bans and forced liquidations affecting investors in Ligand Pharmaceuticals (NASDAQ: LGND). These actions, which occurred on January 28, 2021, and", "url": "https://www.newsfilecorp.com/release/73129/Levi-Korsinsky-LLP-National-Class-Action-Law-Firm-Announces-Class-Action-Investigation-Against-Robinhood-and-Other-Brokers-on-Behalf-of-Investors-in-Ligand-Pharmaceuticals-Incorporated-NASDAQ-LGND?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-06-03T03:39:33", "published_display": "03 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 16, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) CLO sells 5,000 shares, exercises options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQcmttcDlhcG9NRzRxMlZKYXA0YklONlR0V09tU2E1MVBOSTgzRmdJSGVTclRFRjJrSXl6RE9RTmd3ak9qWVc4OXNUbk45WWhkbmxqRm5xeTJDQjh1SlN0TVlwaW9qUWhJc1VZTi05bnlWRVZ1Ylo1eTNESlRveURjaFI5TFozeDcxMDBqSUc2d1ZYWFhFWUNvb1ZfN3A1QjQ2Q2V1cUE0aExpQmR1OXBEbFl3QmVITFREeXVhSA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Ligand Pharmaceuticals (LGND) Investment Story Is Evolving Without Fresh Analyst Targets", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-investment-story-131714147.html", "source_name": "Simply Wall St.", "published_at": "2026-06-01T13:17:14+00:00", "published_display": "01 Jun 2026 13:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (Nasdaq:LGND) - Stock Analysis", "summary": "Ligand Pharmaceuticals (Nasdaq:LGND) is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets. The company recently agreed to acquire XOMA Royalty Corporation for $739 million, significantly expanding its royalty portfolio and leading to an upli", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lgnd/ligand-pharmaceuticals", "source_name": "Simply Wall Street", "published_at": "2026-05-26T11:39:36", "published_display": "26 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LGND: XOMA Buy Adds 100+ Assets", "summary": "Ligand Pharmaceuticals (NASDAQ: LGND) announced the acquisition of XOMA Royalty Corporation (NASDAQ: XOMA) for $739 million, adding over 100 assets to its portfolio. The all-cash transaction, expected to close in Q3 2026, is projected to be immediately accretive to Ligand's earni", "url": "https://scr.zacks.com/news/news-details/2026/LGND-XOMA-Buy-Adds-100-Assets-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-05-20T21:40:32", "published_display": "20 May 2026 21:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals Amends XOMA Royalty Merger Agreement to Add Holding Company", "summary": "Ligand Pharmaceuticals has amended its merger agreement with XOMA Royalty to include XOMA Royalty Holdings, facilitating a Nevada holding company reorganization. This change will result in Ligand's Merger Sub merging with HoldCo, which will then become a wholly owned subsidiary o", "url": "https://www.tradingview.com/news/tradingview:19c64383e002f:0-ligand-pharmaceuticals-amends-xoma-royalty-merger-agreement-to-add-holding-company/", "source_name": "TradingView", "published_at": "2026-05-19T09:10:58", "published_display": "19 May 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) amends XOMA Royalty merger, adds Nevada holding company", "summary": "Ligand Pharmaceuticals (LGND) has amended its merger agreement with XOMA Royalty Corporation to include XOMA Royalty Holdings Corporation as a party, formalizing a Nevada holding company reorganization. This amendment clarifies the legal structure of the previously announced acqu", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-410835941783.html", "source_name": "Stock Titan", "published_at": "2026-05-19T09:10:57", "published_display": "19 May 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stephens Investment Management Group LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated $LGND", "summary": "Stephens Investment Management Group LLC decreased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 9.6% in the fourth quarter, though it remains its 16th largest holding. Despite positive analyst sentiment and a \"Moderate Buy\" consensus rating, the company reported mixed qua", "url": "https://www.marketbeat.com/instant-alerts/filing-stephens-investment-management-group-llc-cuts-stock-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-05-17/", "source_name": "MarketBeat", "published_at": "2026-05-17T14:10:25", "published_display": "17 May 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (LGND) Q1 2026 royalty revenue jumps 56% as guidance reaffirmed", "summary": "Ligand Pharmaceuticals reported strong Q1 2026 results with royalty revenue increasing 56% year-over-year to $43.0 million, primarily driven by products like Filspari, Ohtuvayre, and Capvaxive. Despite a GAAP net loss of $13.3 million due to non-cash items, adjusted net income ro", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-d09558e82e6f.html", "source_name": "Stock Titan", "published_at": "2026-05-14T07:09:22", "published_display": "14 May 2026 07:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Group AG Purchases 31,081 Shares of Ligand Pharmaceuticals Incorporated $LGND", "summary": "UBS Group AG significantly increased its stake in Ligand Pharmaceuticals, purchasing 31,081 additional shares in the fourth quarter, bringing its total holding to 143,067 shares valued at approximately $27.05 million. This comes amidst mixed analyst sentiment, with several firms ", "url": "https://www.marketbeat.com/instant-alerts/filing-ubs-group-ag-purchases-31081-shares-of-ligand-pharmaceuticals-incorporated-lgnd-2026-05-10/", "source_name": "MarketBeat", "published_at": "2026-05-12T07:39:51", "published_display": "12 May 2026 07:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination", "summary": "Ligand Pharmaceuticals (LGND) recently reported an earnings miss, higher royalty revenues, a planned acquisition of XOMA, and a disputed termination of the Viking TR-Beta licensing program. Despite these developments, the stock has shown positive momentum over the past few months", "url": "https://finance.yahoo.com/markets/stocks/articles/look-ligand-pharmaceuticals-lgnd-valuation-111534266.html", "source_name": "Market source", "published_at": "2026-05-10T09:40:30", "published_display": "10 May 2026 09:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals (LGND) Returns To Trailing Profitability Challenging Cautious Earnings Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XOMA Royalty to Be Acquired by Ligand in $39-Per-Share Cash Deal Plus CVRs", "summary": "XOMA Royalty has agreed to be acquired by Ligand Pharmaceuticals for $39.00 per share in cash, plus contingent value rights (CVRs) from RemainCo LLC. The deal awaits HSR clearance and stockholder approval, with key XOMA stakeholders, including BVF Partners, already committed to s", "url": "https://www.tradingview.com/news/tradingview:3c2d28cdec3d4:0-xoma-royalty-to-be-acquired-by-ligand-in-39-per-share-cash-deal-plus-cvrs/", "source_name": "TradingView", "published_at": "2026-05-07T04:09:26", "published_display": "07 May 2026 04:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did Higher 2026 Guidance and XOMA Deal Just Shift Ligand Pharmaceuticals' (LGND) Investment Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand to Participate in May Investor Conferences", "summary": "Ligand Pharmaceuticals announced its senior management team will participate in several investor conferences throughout May 2026, including the H.C. Wainwright Royalty Company Conference, Bank of America Healthcare Conference, CJS Securities Spring 1x1 Conference, H.C. Wainwright", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ligand-participate-may-investor-conferences-200100710.html", "source_name": "Market source", "published_at": "2026-05-05T17:39:52", "published_display": "05 May 2026 17:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?", "summary": "Halper Sadeh LLC, an investor rights law firm, is investigating the sales of XOMA Royalty Corporation, RE/MAX Holdings, Inc., and KalVista Pharmaceuticals, Inc. The firm is examining potential violations of federal securities laws and breaches of fiduciary duties to shareholders,", "url": "https://www.sahmcapital.com/news/content/are-xoma-rmax-kalv-obtaining-fair-deals-for-their-shareholders-2026-05-04", "source_name": "Sahm", "published_at": "2026-05-05T02:09:45", "published_display": "05 May 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard Capital Management files Schedule 13G on Ligand (LGND) showing 5% stake", "summary": "Vanguard Capital Management has filed a Schedule 13G on Ligand Pharmaceuticals Inc. (LGND), reporting a beneficial ownership of 997,637 shares, which represents a 5% stake in the company's common stock as of March 31, 2026. The filing indicates Vanguard possesses sole dispositive", "url": "https://www.stocktitan.net/sec-filings/LGND/schedule-13g-ligand-pharmaceuticals-inc-passive-investment-disclosure-12b076e4bd29.html", "source_name": "Stock Titan", "published_at": "2026-05-01T12:39:09", "published_display": "01 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vanguard reports 5.56% stake in Ligand Pharmaceuticals (NASDAQ: LGND)", "summary": "Vanguard Portfolio Management has reported a 5.56% beneficial ownership stake in Ligand Pharmaceuticals Inc. (NASDAQ: LGND), holding 1,109,154 shares. The Schedule 13G filing indicates sole voting power over 8,887 shares and sole dispositive power over all 1,109,154 shares. This ", "url": "https://www.stocktitan.net/sec-filings/LGND/schedule-13g-ligand-pharmaceuticals-inc-passive-investment-disclosure-de8992a27e47.html", "source_name": "Stock Titan", "published_at": "2026-05-01T12:39:09", "published_display": "01 May 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] LIGAND PHARMACEUTICALS INC Reports Material Event", "summary": "Ligand Pharmaceuticals Inc. (LGND) filed an 8-K report announcing the termination of the TR-Beta Program under its Master License Agreement with Viking Therapeutics, Inc., effective May 4, 2026. Ligand asserts that Viking materially breached its obligation to use commercially rea", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-40920220ed7f.html", "source_name": "Stock Titan", "published_at": "2026-04-30T21:09:42", "published_display": "30 Apr 2026 21:09", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPQXI4bTdBamwzMVNNREMtbTB1OVRfZGNOOFRCYUQ0MUg0aFdMNkg5cG1EY000cDNvTTVrUG5TZGE1SHc1WGlUMHQzNHNxbnVhTEpQQ2NienIzbG8xSVZDLWR6OWRNcU43ejQwVDE0eUdRMWlJZjRqeE1adWtOaTJndU5WN1pDcGpqU09VaEZ4VnhzRXZHengxYVhpTmY2cDQ3SHp0Zw?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B. Metzler seel. Sohn & Co. AG Invests $1.30 Million in Ligand Pharmaceuticals Incorporated $LGND", "summary": "B. Metzler seel. Sohn & Co. AG has invested $1.30 million in Ligand Pharmaceuticals (NASDAQ:LGND) by purchasing 6,879 shares in Q4, bringing institutional ownership to approximately 91.28%. Despite this, company insiders, including the CFO and a director, have recently sold share", "url": "https://www.marketbeat.com/instant-alerts/filing-b-metzler-seel-sohn-co-ag-invests-130-million-in-ligand-pharmaceuticals-incorporated-lgnd-2026-04-27/", "source_name": "MarketBeat", "published_at": "2026-04-28T00:39:09", "published_display": "28 Apr 2026 00:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand Pharmaceuticals to Acquire XOMA Royalty for $39 Per Share Plus CVRs", "summary": "Ligand Pharmaceuticals has entered into a definitive merger agreement to acquire XOMA Royalty for $39.00 per share in cash, along with contingent value rights (CVRs) tied to a CVR Trust. The deal is contingent on XOMA Royalty stockholder approval, HSR clearance, and a holding com", "url": "https://www.tradingview.com/news/tradingview:80f3a7f8fea2d:0-ligand-pharmaceuticals-to-acquire-xoma-royalty-for-39-per-share-plus-cvrs/", "source_name": "TradingView", "published_at": "2026-04-28T00:39:09", "published_display": "28 Apr 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (Nasdaq: LGND) to acquire XOMA Royalty in $739M, EPS\u2011accretive deal", "summary": "Ligand Pharmaceuticals announced its agreement to acquire XOMA Royalty Corporation for $739 million in cash, equating to $39.00 per share plus a contingent value right tied to Janssen litigation proceeds. This acquisition will significantly expand Ligand's biopharma royalty portf", "url": "https://www.stocktitan.net/sec-filings/LGND/8-k-ligand-pharmaceuticals-inc-reports-material-event-67f9ae07b50f.html", "source_name": "Stock Titan", "published_at": "2026-04-28T00:09:42", "published_display": "28 Apr 2026 00:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Impax Asset Management Group plc Sells 35,000 Shares of Ligand Pharmaceuticals Incorporated $LGND", "summary": "Impax Asset Management Group plc reduced its stake in Ligand Pharmaceuticals Incorporated by 17.5%, selling 35,000 shares and now holding 165,208 shares valued at approximately $31.24 million. Despite this sale, Ligand Pharmaceuticals reported strong quarterly results with EPS of", "url": "https://www.marketbeat.com/instant-alerts/filing-impax-asset-management-group-plc-sells-35000-shares-of-ligand-pharmaceuticals-incorporated-lgnd-2026-04-25/", "source_name": "MarketBeat", "published_at": "2026-04-25T13:10:14", "published_display": "25 Apr 2026 13:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assetmark Inc. Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND", "summary": "Assetmark Inc. significantly increased its stake in Ligand Pharmaceuticals (NASDAQ:LGND) by 4,933.3%, now owning 6,191 shares valued at approximately $1.17 million. Analysts maintain a \"Moderate Buy\" consensus with a price target of $247.29, following strong quarterly earnings wh", "url": "https://www.marketbeat.com/instant-alerts/filing-assetmark-inc-raises-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-04-22/", "source_name": "MarketBeat", "published_at": "2026-04-22T10:08:52", "published_display": "22 Apr 2026 10:08", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ligand (NASDAQ: LGND) posts strong 2025 growth and seeks approval for expanded equity plan", "summary": "Ligand Pharmaceuticals (LGND) is seeking stockholder approval for an expanded equity plan at its June 5, 2026, annual meeting, following a strong financial performance in 2025. The company reported a 48% increase in royalty revenue and a 42% rise in adjusted EPS, driven by its ro", "url": "https://www.stocktitan.net/sec-filings/LGND/def-14a-ligand-pharmaceuticals-inc-definitive-proxy-statement-ce0cc5d0efc1.html", "source_name": "Stock Titan", "published_at": "2026-04-21T20:40:15", "published_display": "21 Apr 2026 20:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 110, "total_relevant": 71, "sentiment_summary": {"positive": 19, "negative": 5, "neutral": 47, "score": 55, "total": 71, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 7.84, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 5.85, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 274.88, "latest_week": "2026-06-19", "one_week_move": 7.6, "four_week_move": 19.9, "twelve_week_move": 40.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.176053, "market_dynamics_buy_signal": false, "relative_strength": 21.217395, "fair_value_gap": 124.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.6077, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.6% over one week, +19.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 21}, {"label": "Market source", "count": 7}, {"label": "simplywall.st", "count": 6}, {"label": "MarketBeat", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "MT Newswires", "count": 4}, {"label": "GlobeNewswire", "count": 2}, {"label": "Trefis", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 64}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 10}, {"label": "Analyst action", "count": 4}, {"label": "Guidance", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "64", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.6% over one week, +19.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Ligand Pharmaceuticals Incorporated Stock 12\u2011Month Price Target Raised to $278.5, Implies 1% Upside"}], "updated_at": "2026-06-23T02:16:29.370082+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}